Potential of cell-free hemoglobin and haptoglobin as prognostic markers in patients with ARDS and treatment with veno-venous ECMO.

Victoria BüngerOliver HunsickerAlexander KrannichFelix BalzerClaudia D SpiesWolfgang M KueblerSteffen Weber-CarstensMario MenkJan A Graw

Published in: Journal of intensive care (2023)

Moderate hemolysis with mCFH-levels as low as 11 mg/dl impacts mortality in patients with ARDS and therapy with veno-venous ECMO. Furthermore, a cumulative dose effect should be considered indicated by the relative therapy days with CFH-concentrations > 11 mg/dl. In addition, also Hp plasma concentrations need consideration when the injurious effect of elevated CFH is evaluated.

Keyphrases

extracorporeal membrane oxygenation
acute respiratory distress syndrome
cell free
respiratory failure
mechanical ventilation
type diabetes
intensive care unit
risk factors
climate change
combination therapy
smoking cessation
cell therapy
human health
replacement therapy
red blood cell